Prasugrel in the treatment of acute coronary syndrome

Dual antiplatelet therapy is the mainstay therapy in patients with acute coronary syndrome. The combination of aspirin and a P2Y12 inhibitor in patients who receive a coronary stent reduces the rate of stent thrombosis and the rates of major adverse cardiovascular events. The newer P2Y12 inhibitors...

Full description

Saved in:
Bibliographic Details
Published in:Future cardiology 2020-11, Vol.16 (6), p.559-568
Main Authors: Spartalis, Michael, Tzatzaki, Eleni, Spartalis, Eleftherios, Paschou, Stavroula A, Athanasiou, Antonios, Iliopoulos, Dimitrios C, Siasos, Gerasimos, Voudris, Vassilis
Format: Article
Language:English
Subjects:
ACS
acute coronary syndrome
cardiovascular
clopidogrel
coronary
prasugrel
ticagrelor
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dual antiplatelet therapy is the mainstay therapy in patients with acute coronary syndrome. The combination of aspirin and a P2Y12 inhibitor in patients who receive a coronary stent reduces the rate of stent thrombosis and the rates of major adverse cardiovascular events. The newer P2Y12 inhibitors (prasugrel and ticagrelor) have better efficacy than clopidogrel. Prasugrel provides greater inhibition of platelet aggregation and has a rapid onset of action. Current acute coronary syndrome guidelines recommend the use of both newer P2Y12 inhibitors. However, emerging data have shown that prasugrel is more efficient than ticagrelor in reducing the incidence of nonfatal myocardial infarction, stroke or cardiovascular death, without increased risk of major bleeding.
ISSN:1479-6678
1744-8298
DOI:10.2217/fca-2020-0018